Solriamfetol
Solriamfetol is a wake-promoting medicine for adults that treats excessive daytime sleepiness caused by narcolepsy or obstructive sleep apnea (OSA).
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Solriamfetol (Sunosi) is a newer wake-promoting medicine, on the market since about 2019, for adults with excessive daytime sleepiness from narcolepsy or obstructive sleep apnea (OSA). It blocks the reabsorption of dopamine and norepinephrine, two brain chemicals that drive alertness. Most people tolerate it fairly well, and headache, nausea, a smaller appetite and jitteriness are the usual complaints. The thing to watch is blood pressure and heart rate, which it raises more at higher doses, so have both checked before starting and regularly after. With OSA, keep using CPAP, since Sunosi treats the sleepiness, not the blocked airway.
Clinical pearls
- Take it right after waking, with or without food, and never within 9 hours of bedtime or sleep suffers.
- Never combine it with an MAO inhibitor or within 14 days of stopping one, because blood pressure can spike dangerously.
- It is a Schedule IV controlled substance, so refills follow tighter rules and the tablets should be stored securely.
- Moderate or severe kidney disease calls for a lower dose, and it is not recommended in end-stage kidney disease.
Patient information guide A plain-language walkthrough of Solriamfetol, written from its FDA label.
What Solriamfetol is used for
▾
Solriamfetol is used to improve wakefulness in adults. Sunosi tablets are approved for:
- Excessive daytime sleepiness from narcolepsy
- Excessive daytime sleepiness from obstructive sleep apnea (OSA)
It does not treat the airway blockage in OSA, so CPAP or similar treatment should continue.
How Solriamfetol works
▾
Solriamfetol blocks the reuptake (reabsorption) of dopamine and norepinephrine, two brain chemicals involved in alertness. This may be how it improves wakefulness, although the exact mechanism is unclear.
It does not block serotonin reuptake and shows no meaningful binding to many other receptors.
Solriamfetol dosage
▾
Sunosi tablets are taken by mouth once a day after waking, with or without food. Avoid taking them within 9 hours of bedtime.
- Your prescriber chooses a starting dose based on whether you have narcolepsy or OSA.
- The dose can be increased gradually based on how well it works and how you tolerate it.
- People with kidney problems need lower doses.
- The 75 mg tablet is scored and can be split in half.
Follow your prescriber and the label for exact directions.
Dosing details from the FDA-approved label
From the Solriamfetol prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Narcolepsy (adults)
- Initiate at 75 mg once daily upon awakening
- Recommended dose range 75 mg to 150 mg once daily
- Dosage may be doubled at intervals of at least 3 days based on efficacy and tolerability
- Maximum: 150 mg once daily
- Avoid taking within 9 hours of planned bedtime; take with or without food
- Obstructive sleep apnea (OSA) (adults)
- Initiate at 37.5 mg once daily upon awakening
- Recommended dosage range 37.5 mg to 150 mg once daily
- Dosage may be doubled at intervals of at least 3 days based on efficacy and tolerability
- Maximum: 150 mg once daily
- Avoid taking within 9 hours of planned bedtime; take with or without food
- Moderate renal impairment (eGFR 30-59 mL/min/1.73 m2)
- Initiate dosing at 37.5 mg once daily
- Based on efficacy and tolerability, may be increased after at least 7 days
- Maximum: 75 mg once daily
- Renal dose adjustment
- Severe renal impairment (eGFR 15-29 mL/min/1.73 m2)
- Administer 37.5 mg once daily
- Maximum: 37.5 mg daily
- Renal dose adjustment
- End stage renal disease (ESRD)
- Not recommended
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION Administer once daily upon awakening. Avoid administration within 9 hours of planned bedtime because of the potential to interfere with sleep. ( 2.2 ) Starting dose for patients with narcolepsy: 75 mg once daily. ( 2.3 ) Starting dose for patients with OSA: 37.5 mg once daily. ( 2.4 ) Dose may be increased at intervals of at least 3 days. ( 2.3 , 2.4 ) Maximum dose is 150 mg once daily. ( 2.3 , 2.4 ) Renal impairment ( 2.5 , 8.6 , 12.3 ): Moderate impairment: Starting dose is 37.5 mg once daily. May increase to 75 mg once daily after at least 7 days. Severe impairment: Starting dose and maximum dose is 37.5 mg once daily. End stage renal disease (ESRD): Not recommended. 2.1 Important Considerations Prior to Initiating Treatment Prior to initiating treatment with SUNOSI, ensure blood pressure is adequately controlled [see Warnings and Precautions ( 5.1 )] . 2.2 General Administration Instructions Administer SUNOSI orally upon awakening with or without food. Avoid taking SUNOSI within 9 hours of planned bedtime because of the potential to interfere with sleep if taken too late in the day. SUNOSI 75 mg tablets are functionally scored tablets that can be split in half (37.5 mg) at the score line. 2.3 Dosage in Narcolepsy Initiate SUNOSI at 75 mg once daily in adults with narcolepsy. The recommended dose range for SUNOSI is 75 mg to 150 mg once daily. Based on efficacy and tolerability, the dosage of SUNOSI may be doubled at intervals of at least 3 days. The maximum recommended dose is 150 mg once daily. Dosages above 150 mg daily do not confer increased effectiveness sufficient to outweigh dose-related adverse reactions [see Warnings and Precautions ( 5.1 )] . 2.4 Dosage in OSA Initiate SUNOSI at 37.5 mg once daily in adults with OSA. The recommended dosage range for SUNOSI is 37.5 mg to 150 mg once daily. Based on efficacy and tolerability, the dosage of SUNOSI may be doubled at intervals of at least 3 days. The maximum recommended dosage is 150 mg once daily. Dosages above 150 mg daily do not confer increased effectiveness sufficient to outweigh dose-related adverse reactions [see Warnings and Precautions ( 5.1 )] . 2.5 Dosage Recommendations in Patients with Renal Impairment Moderate renal impairment (eGFR 30-59 mL/min/1.73 m 2 ) : Initiate dosing at 37.5 mg once daily.
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Solriamfetol side effects
▾
The most common side effects in studies were:
Common side effects
- Headache
- Nausea
- Decreased appetite
- Trouble sleeping (insomnia)
- Anxiety
- Dry mouth
- Palpitations (feeling your heartbeat)
- Feeling jittery
- Diarrhea or constipation
When to get medical help
- Call your doctor if you notice a pounding or fast heartbeat, chest discomfort or chest pain.
- Call your doctor if your blood pressure or heart rate keeps rising.
- Tell your doctor if new or worsening anxiety, insomnia, irritability, agitation or other psychiatric symptoms appear.
- Seek medical help for rash, hives or other allergic-type reactions.
Several of these were more common at higher doses. Contact your doctor about chest pain, a racing heartbeat, rising blood pressure, worsening anxiety or mood symptoms, or rash and hives.
Solriamfetol warnings and precautions
▾
- Blood pressure and heart rate: Sunosi raises both, depending on dose. Control high blood pressure first and have it checked regularly.
- Heart conditions: Avoid use with unstable cardiovascular disease, serious arrhythmias or other serious heart problems.
- Psychiatric symptoms: Anxiety, insomnia and irritability can occur. Use caution with a history of psychosis or bipolar disorder.
- Kidney impairment: The drug lingers longer, which may raise the risk of these effects.
Solriamfetol interactions
▾
A few medicine types need special care with solriamfetol:
- MAO inhibitors: Never combine, or take within 14 days of stopping one. This risks a dangerous hypertensive reaction.
- Drugs that raise blood pressure or heart rate: Not studied together, so use caution.
- Dopaminergic drugs: May interact with it. Not studied, so use caution.
Interactions listed in the FDA-approved label
From the Solriamfetol prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Monoamine oxidase (MAO) inhibitors: Concomitant use of MAO inhibitors and noradrenergic drugs may increase the risk of a hypertensive reaction; potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Do not administer SUNOSI concomitantly with MAOIs or within 14 days after discontinuing MAOI treatment.
- Drugs that increase blood pressure and/or heart rate: Concomitant use with SUNOSI has not been evaluated. Such combinations should be used with caution.
- Dopaminergic drugs: Drugs that increase levels of dopamine or bind directly to dopamine receptors might result in pharmacodynamic interactions with SUNOSI; interactions have not been evaluated. Use caution when concomitantly administering dopaminergic drugs with SUNOSI.
Read the label’s full interactions text
7 DRUG INTERACTIONS Drugs that Increase Blood Pressure and/or Heart Rate and Dopaminergic Drugs : Use caution when co-administering with SUNOSI. ( 7.2 , 7.3 ) 7.1 Monoamine Oxidase (MAO) Inhibitors Do not administer SUNOSI concomitantly with MAOIs or within 14 days after discontinuing MAOI treatment. Concomitant use of MAO inhibitors and noradrenergic drugs may increase the risk of a hypertensive reaction. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure [see Contraindications ( 4 )]. 7.2 Drugs that Increase Blood Pressure and/or Heart Rate Concomitant use of SUNOSI with other drugs that increase blood pressure and/or heart rate has not been evaluated, and such combinations should be used with caution [see Warnings and Precautions ( 5.1 )]. 7.3 Dopaminergic Drugs Dopaminergic drugs that increase levels of dopamine or that bind directly to dopamine receptors might result in pharmacodynamic interactions with SUNOSI. Interactions with dopaminergic drugs have not been evaluated with SUNOSI. Use caution when concomitantly administering dopaminergic drugs with SUNOSI.
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Solriamfetol
▾
- Do not use with an MAO inhibitor or within 14 days of stopping one.
- Tell your doctor about high blood pressure or heart problems.
- Tell your doctor about psychosis or bipolar disorder.
- Kidney disease requires dose adjustment. It is not recommended in end stage kidney disease.
- Older adults may need lower doses and closer monitoring.
- Pregnancy: human data are limited. A pregnancy registry exists.
- Breastfeeding: the drug passes into milk. Watch infants for agitation, insomnia and poor weight gain.
- Not established for children.
Solriamfetol overdose
▾
There is no specific reversal agent for Sunosi. Overdose is managed with supportive care, including heart monitoring. Call Poison Control at 1-800-222-1222 for guidance.
What Solriamfetol does in the body
▾
Solriamfetol weakly blocks the transporters that clear dopamine and norepinephrine, with no meaningful effect on serotonin reuptake. It raises heart rate and blood pressure. In a study of healthy people, heart rate rose noticeably at higher doses. At a dose twice the maximum recommended, it did not prolong the QTc interval (a heart rhythm measurement) to a clinically relevant extent.
How your body processes Solriamfetol
▾
Solriamfetol is well absorbed by mouth and peaks in about 2 hours. A high-fat meal delays the peak by about an hour but changes total exposure very little. It is barely metabolized, and about 95% leaves the body unchanged in urine. Its half-life is about 7 hours, and steady levels are reached in about 3 days. Kidney impairment lengthens the half-life.
How to store Solriamfetol
▾
Store SUNOSI at 20 to 25°C (68°to 77°F); excursions permitted between 15°to 30°C (59°to 86°F) (see USP controlled room temperature).
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Solriamfetol
61 supplements and herbal products have documented interactions with Solriamfetol in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 5
- Moderate · 43
- Minor · 13
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Solriamfetol: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Solriamfetol — the kind of thing our pharmacy team would talk through with you at the counter.
What is Sunosi for?
▾
When should I take it?
▾
What side effects should I expect?
▾
Does it affect my blood pressure or heart?
▾
What can't I take with it?
▾
Is it safe in pregnancy or while breastfeeding?
▾
Is Solriamfetol available over the counter?
▾
Is Solriamfetol a controlled substance?
▾
When was Solriamfetol first available?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Solriamfetol on HelloPharmacist
Solriamfetol forms and strengths (how it comes)
Solriamfetol is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Solriamfetol inactive ingredients by manufacturer.
Tablet
How this form is used
- Sunosi improves wakefulness in adults with excessive daytime sleepiness from narcolepsy or obstructive sleep apnea.
- Sunosi is taken by mouth once daily on waking, with or without food.
- Avoid taking Sunosi within 9 hours of planned bedtime.
- Sunosi 75 mg tablets are scored and can be split in half at the score line.
Solriamfetol on the U.S. market: products, makers and brands
How Solriamfetol appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
1 company lists 2 Solriamfetol product records with the FDA, mostly as tablet; the earliest marketing or approval year on record is 2019. Brand names on the directory include Sunosi; the rest are generics.
Also listed with the FDA, not a patient dose form: Powder (4) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
How widely Solriamfetol is used (Medicaid data)
A general measure of how commonly Solriamfetol is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Solriamfetol is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Solriamfetol prescribed? Of the 1,601 medications we measure, Solriamfetol ranks #854 by Medicaid prescriptions — more than 47% of them.
Utilization by Solriamfetol product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
solriamfetol 150 MG Oral Tablet Most dispensed
Summed across the 1 of 8 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2121758
solriamfetol 75 MG Oral Tablet
Summed across the 1 of 9 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2121756
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Solriamfetol, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 2 of 17 listed Solriamfetol NDCs with Medicaid activity.
Compare Solriamfetol products
A representative set of FDA-listed product records for Solriamfetol — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Tablet | ||||
| 75 mg | Oral | Axsome Therapeutics, Inc. | NDA | View NDC → |
| 150 mg | Oral | Axsome Therapeutics, Inc. | NDA | View NDC → |
Showing 2 of 2 products — FDA National Drug Code Directory. See every product, package size and price: browse all 2 Solriamfetol NDCs →
Solriamfetol side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Solriamfetol — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Solriamfetol in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Solriamfetol FDA approval history
How Solriamfetol went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Solriamfetol recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Solriamfetol recalls since July 2021.
✅No Solriamfetol recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 2121751 1 dose form · 2 strengths
-
Dose form (SCDF) Oral Tablet RxCUI 2121755In current FDA listings
Look up RxCUI 2121751 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Solriamfetol supply and shortage status
Whether Solriamfetol is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
💵 What Solriamfetol costs pharmacies (NADAC benchmark)
The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.
| Form | Strength | Pharmacy acquisition benchmark | |
|---|---|---|---|
| Tablet, Film Coated · Oral | 75 mg | $27.79–$31.37 per tablet | NDC details & price history |
| Tablet, Film Coated · Oral | 150 mg | $27.91–$31.34 per tablet | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.
Solriamfetol brand names
Solriamfetol is sold under one brand name in the FDA directory — Sunosi. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Solriamfetol: manufacturers and labelers
One company lists Solriamfetol products with the FDA. By number of product records, the largest are Axsome Therapeutics, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Solriamfetol drug class (RxNorm)
Solriamfetol belongs to the Dopamine and Norepinephrine Reuptake Inhibitor class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Solriamfetol page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Axsome Therapeutics, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →